

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/35, 9/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/32107</b> <b>(43) International Publication Date:</b> 1 July 1999 (01.07.99)
<b>(21) International Application Number:</b> PCT/GB98/03703 <b>(22) International Filing Date:</b> 10 December 1998 (10.12.98) <b>(30) Priority Data:</b> 9726916.1 19 December 1997 (19.12.97) GB <b>(71) Applicant (for all designated States except US):</b> DANBIOSYST UK LIMITED [GB/GB]; Albert Einstein Centre, Highfields Science Park, Nottingham NG7 2TN (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WATTS, Peter, James [GB/GB]; Flat 2, 47 Highfield Road, West Bridgford, Nottingham NG2 6DR (GB). DAVIS, Stanley, Stewart [GB/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB). <b>(74) Agent:</b> BASSETT, Richard; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COMPOSITIONS COMPRISING CANNABINOIDS  <b>(57) Abstract</b>  There is provided a composition for the nasal delivery of a cannabinoid which comprises a cannabinoid in a biphasic delivery system or a cannabinoid in a microsphere delivery system.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## COMPOSITIONS COMPRISING CANNABINOIDS

This invention relates to pharmaceutical compositions for nasal delivery of cannabinoids and pharmaceutically acceptable salts and prodrugs thereof.

- 5 The present invention also relates to the delivery of cannabinoids across the nasal mucosa of animals, especially humans, for the treatment of conditions such as pain, nausea and to stimulate appetite.

It is known that the active ingredients of cannabis, in the form of  
10 cannabinoids, can be useful in medical practice. The material delta-9-tetrahydrocannabinol (THC) is useful in the treatment of AIDS (J. Pain. Symptom Manage. 1995, 10, 89-97) when given orally. The drug is called Dronabinol and is formulated in sesame oil for oral delivery. The material is available commercially as the product Marinol® sold by Roxane in the  
15 USA.

Dronabinol (9-delta THC or THC) exhibits complex effects on the central nervous system (CNS), including central sympathomimetic activity. Dronabinol has been shown to have a marked appetite stimulant effect and  
20 has been used in the treatment of AIDS-related anorexia. Dronabinol also demonstrates effects on mood, cognition, memory and perception. Furthermore, the drug has anti-emetic properties and is used for the control of nausea and vomiting associated with cancer chemotherapy. These effects appear to be dose related. After oral administration,  
25 Dronabinol has an onset of action of approximately 0.5 to 1 hour and a peak effect at 2 - 4 hours. The duration of action for psychoactive effects is 4 - 6 hours, but the appetite stimulant effect may continue for 24 hours or longer after administration. Dronabinol is almost completely absorbed (90-95%) after single oral doses. However, due to a combined effect of

first pass hepatic metabolism and high lipid solubility only 10-20% of the administered dose reaches the systemic circulation.

Studies on the use of THC in pain have been described in Pharm. J. 259,  
5 104, 1997 and in Pharm. Sci. 3, 546, 1997. Nabilone, a synthetic  
cannabinoid has been reported to be an anti-emetic and anxiolytic, and  
also useful for treating pain of various etiologies such as multiple sclerosis  
(MS), peripheral neuropathy and spinal injuries (Lancet, 1995, 345, 579,  
Pharm. J. 259, 104, 1997). It is also known that inhaling cannabis by  
10 smoking can lead to a more rapid onset of action than oral ingestion.

A nasal formulation for the improved delivery of cannabinoids would be  
advantageous. Absorption of drugs from the nasal route tends to be rapid  
due to the large surface area available and the extensive blood supply. In  
15 addition, the drug is delivered directly to the systemic circulation and  
there is no loss due to "first pass" metabolism in the liver.

The nasal route is known to provide advantages for the delivery of drugs,  
and for some drugs the pharmacokinetic profile following nasal  
20 administration is similar to that found after intravenous administration.  
However, THC is in the form of an oily liquid which is highly lipid  
soluble and only sparingly soluble in water. Hence, the person skilled in  
the art would consider it impossible to produce a simple nasal solution or  
other simple gel or suspension formulation that could produce sufficient  
25 nasal absorption and therapeutic plasma levels.

The nasal administration of cannabinoids and their analogues has been  
described in US-4464378. It was suggested that the drugs would be  
administered as simple nasal sprays, ointments, gels or suspensions,

though no examples of formulations produced with THC were described. As explained above, the person skilled in the art would not expect such simple formulations of THC to be successful due to the low water solubility.

5

We have found surprisingly that cannabinoids and especially THC can be formulated successfully into a nasal product by using a biphasic delivery system and that such a biphasic delivery system provides improved nasal absorption and therapeutically relevant plasma levels. We have also found  
10 surprisingly that cannabinoids and especially THC can be delivered successfully via the nasal route by formulating into a microsphere system and particularly an albumin microsphere system.

According to a first aspect of the present invention there is provided a  
15 composition for the nasal delivery of a cannabinoid comprising a cannabinoid in a biphasic delivery system.

According to a second aspect of the present invention there is provided a composition for the nasal delivery of a cannabinoid comprising a  
20 cannabinoid in a microsphere delivery system.

By the term "cannabinoid" we include, inter alia, delta-8-tetrahydrocannabinol, delta-9-tetrahydrocannabinol, cannabidiol, olivetol, cannabinol, cannabigerol, nabilone, delta-9-tetrahydro cannabinotic acid.  
25 The non-psychotropic cannabinoid 3-dimethylnepthyl 11 carboxylic acid homologue 8, delta-8-tetrahydrocannabinol, (J. Med. Chem. 35, 3135, 1992) as well as the prodrugs and pharmaceutically acceptable salts of cannabinoids are also suitable for the present invention and are included in the term "cannabinoid". A suitable prodrug is THC-hemisuccinate.

By a "biphasic delivery system" we are referring to a pharmaceutical composition comprising two phases of which one phase contains the dissolved, dispersed, solubilised or dissolved drug and the other phase provides the carrier for the composition, for example the outer (surrounding) water phase in an emulsion system or the matrix of a microcapsule or microsphere system.

By "improved nasal absorption" we mean more than 10%, preferably more than 20% and most preferably more than 30% bioavailability of the drug after nasal administration. By the term bioavailability, we mean the absorption of the drug as measured by the area under the plasma level versus time profile following nasal administration as compared to the same parameter when the drug is given by intravenous injection; the values for the area being corrected for the dose of the drug if necessary.

Biphasic delivery systems may be in the form of emulsion systems, such as an oil-in-water (O/W) emulsion, aqueous systems containing a solubilising or dispersing agent or microsphere systems where the phase containing the drug can be encapsulated by or dispersed on the surface of the microspheres.

An oil-in-water emulsion can be prepared using a combination of a pharmaceutically acceptable oil and emulsifier. The drug is dissolved in the oil phase which is then mixed with an aqueous phase typically containing a stabiliser under vigorous mixing, milling or homogenisation. Such emulsification methods are well described by Idson, Pharmaceutical Emulsions, Ch. 6, Pharmaceutical Dosage Forms, Disperse Systems. Vol.1. Ed. Lieberman et al. Dekker, New York, 1988.

Preferred oils are vegetable oils such as soybean oil, olive oil, cotton seed oil, peanut oil, sesame oil and castor oil, with sesame oil and castor oil being preferred.

- 5 Vitamin E (tocopherol) can also be used as the oil phase. This material is also an antioxidant and can help to stabilise the chosen cannabinoid which tend to be prone to oxidation.

By the term Vitamin E (tocopherol) we include the  $\alpha$ -,  $\beta$ -,  $\gamma$ - and  $\delta$ - forms  
10 of tocopherol that differ by the number and position of methyl groups on the chromanol ring as well as the various isomers of these compounds. Pharmaceutically acceptable derivatives of tocopherol are also included, such as the esters of tocopherol, e.g. the linoleate, nicotinate, acetate or acid succinate ester.

15

The United States Pharmacopoeia describes Vitamin E as a form of  $\alpha$ -tocopherol. This includes d- or d, l- $\alpha$ -tocopherol, d- or d, l- $\alpha$ -tocopherol acetate and d- or d, l- $\alpha$ -tocopherol succinate. The term Vitamin E is also used as a generic description for all tocopherol and tocotrienol derivatives  
20 that exhibit Vitamin E activity. Thus, the term tocopherols is synonymous with Vitamin E, but also for methyl tocols.

A preferred Vitamin E composition for use in the emulsions of the present invention is  $\alpha$ -tocopherol as described in the United States  
25 Pharmacopoeia, Volume 23, 1995 which is also known as all-rac- $\alpha$ -tocopherol. This material can be obtained from Roche Products Ltd., Heanor, UK.

The chosen emulsifier will be one that confers good stability to the emulsion and is pharmaceutically acceptable.

One preferred emulsifier is a block copolymer containing a polyoxyethylene block, i.e. a block made up of repeating ethylene oxide moieties. A suitable emulsifier of this type is Poloxamer, i.e. a polyoxyethylene-polyoxypropylene block copolymer, such as Poloxamer 188. See the Handbook of Pharmaceutical Excipients, p.352, 2nd Edn. Pharmaceutical Press, London, 1994, Eds, Wade and Weller.

10

Another preferred emulsifier is a phospholipid emulsifier. This can be any pharmaceutically acceptable material derived from soybeans or eggs, e.g. soy or egg lecithins. Egg lecithins, such as the material provided by Lipoid (Germany) known as Lipoid E80, which contains both phosphatidylcholine and phosphatidyl ethanolamine, are preferred, although other phospholipid materials could be used including phospholipid-polyethylene glycol (PEG) conjugates (PEGylated phospholipids) that have been described for use in liposome systems, e.g. by Litzinger et al, Biochem Biophys Acta, 1190 (1994) 99-107.

20

The stability of the emulsion can be enhanced by the addition of a pharmaceutically acceptable co-emulsifier. Suitable co-emulsifiers include the fatty acids and salts thereof and bile acid and salts thereof. Suitable fatty acids are those having greater than 8 carbon atoms in their structure with oleic acid being a preferred material. A preferred bile acid is deoxycholic acid. Suitable salts are the pharmaceutically acceptable salts such as the alkali metal, e.g. Na and K, salts. These co-emulsifiers can be added at a concentration of 1% w/v, i.e. 1g of co-emulsifier per 100 mls,



or less of the total emulsion. Bile salts and oleic acid are preferred co-emulsifiers.

5 The quantity of oil in the emulsion can be from 5 to 50% on a v/v basis, preferably from 10 to 50% v/v and more preferably from 15 to 25% v/v. The drug is typically dissolved in the oil phase at a concentration of 0.1 to 20 % w/v, preferably from 1 to 10% w/v, i.e. from 0.1 to 20, preferably from 1 to 10 g of drug in 100 ml of oil.

10 The emulsion formulation can be delivered to the nasal cavity using nasal spray devices known in the art such as those available from Pfeiffer and Valois. Such devices are familiar to the skilled artisan and can be single or multiple dosing systems.

15 The preferred volume for nasal administration is 150  $\mu$ l (per nostril) containing a dose of about 1 mg of THC.

The biphasic delivery systems may also comprise a solubilising agent (solubilising phase) in an aqueous phase or in a solid phase. The  
20 solubilisation of the cannabinoid may be achieved by the use of a cyclodextrin or derivative thereof. Cyclodextrins are cyclic oligosaccharides which comprise glucopyranose units and cyclodextrins for use as pharmaceutical excipients have been described in detail by Thompson, Crit. Rev. Ther. Drug Carrier Sept. 14 1 (1997).  
25 Cyclodextrin and cyclodextrin derivatives which may be useful in the present invention include  $\alpha$ -cyclodextrin,  $\beta$ -cyclodextrin,  $\gamma$ -cyclodextrin, hydroxypropyl- $\beta$ -cyclodextrin, dimethyl- $\beta$ -cyclodextrin, sulphobutylether cyclodextrin, 2,6-dimethyl 14- $\beta$  cyclodextrin, 2, 3, 6- trimethyl 21- $\beta$  cyclodextrin.

The solubilising agent/cannabinoid formulation can be a simple aqueous product in which the drug is associated with the solubilising agent molecule, e.g. as a guest-host complex in which the drug (guest) is contained within a cavity in the solubilising agent molecule (host).  
5 Alternatively, the solubilising agent/cannabinoid formulation can be combined with the emulsion product described earlier when some of the drug can be present in the aqueous phase of the emulsion, solubilized in the solubilising agent, and a proportion of the drug can be present  
10 dissolved in the oil phase of the emulsion.

Alternatively, a guest-host product between a solubilising agent and a cannabinoid can be freeze dried to produce a powder material and then mixed with a bioadhesive microsphere such as a bioadhesive swelling  
15 starch microsphere as described in PCT/GB88/00836.

Other bioadhesive microspheres that may be used in the present compositions include those made from chitosan, polyvinyl pyrrolidone, alginate, polycarbophil, pectin, hyaluronic acid (and esters thereof), agar  
20 agarose, dextran, ovalbumin, collagen, casein.

By bioadhesion we mean a material that can interact with mucus or a mucosal surface and thereby provide retention of a drug at a mucosal surface for a period of time longer than that found for a simple liquid or  
25 powder system. The concept of bioadhesion has been well discussed in books and reviews such as Bioadhesive Drug Delivery Systems, Ed. Lenaerts and Gurney, CRC Press, Boca Raton, 1990 and Bioadhesion possibilities and future trends. Ed. Gurney and Junginger, Wissenschaftliche, Verlagsgesellschaft mbh, Stuttgart, 1990.

Such a system will demonstrate good stability with high bioavailability when administered via the nasal route.

- 5 The weight ratio of solubilising agent to cannabinoid is typically in the range of from 100:1 to 5:1, preferably in the range of from 50:1 to 10:1 and more preferably in the range of from 30:1 to 10:1. The weight ratio of solubilising agent/cannabinoid guest-host product to carrier, e.g. water or microspheres, can be varied but is typically in the range of from 1:100 to  
10 1:5, preferably in the range of from 1:50 to 1:10 and particularly in the range of from 1:25 to 1:15.

The systems containing a solubilising agent can also be mixed with a gelling system based on a polysaccharide such as gellan or pectin. These  
15 materials can be used to formulate a nasal liquid that can be sprayed into the nasal cavity but will then gel in the presence of endogenous cations. This gelling may prolong the contact time of the formulation in the nasal cavity either through bioadhesive interactions and/or the increase in viscosity. Pectin is a preferred material which can form gels in the  
20 presence of divalent cations such as calcium. Pectins with a low degree of esterification, i.e. less than 50%, for example, less than 35%, are suitable and these can be obtained from Copenhagen Pectin A/S as the commercial material known as Slendid Type 100 and Slendid Type 110. These pectins have been extracted from citrus peel and standardised by the addition of  
25 sucrose. The degree of esterification is less than 50% for both pectins and of the order of 10 % for type 100 and 35% for type 110. Further suitable materials include GENU pectin types LM1912CS and Pomosin pectin types LM12CG and LM18CG. The concentration of pectin in the

composition can be from 0.1 % to 10% w/w, but is preferably from 0.5 to 5% w/w on the total weight of the composition.

The powdered product can be delivered nasally using an insufflator device  
5 of the type which is familiar to those skilled in the art. Such devices are manufactured by Teijin (Rhinocort™ insufflator), Bepak UK (nasal delivery device), Valois Monopoudre™, France.

A further embodiment of this invention is to incorporate a cannabinoid  
10 into a microsphere. It has been found that cannabinoids can be loaded into albumin microspheres and that it is possible to recover such microspheres in a dry powder for nasal administration. Other materials suitable for the preparation of microspheres include agar, alginate, chitosan, starch, hydroxyethyl starch, ovalbumin, agarose, dextran, hyaluronic acid,  
15 gelatin, collagen and casein. The microspheres can be produced by various processes known to the person skilled in the art such as a spray drying process or an emulsification process.

For example, albumin microspheres can be prepared by adding rabbit  
20 serum albumin in phosphate buffer to olive oil with stirring to produce a water in oil emulsion. Glutaraldehyde solution is then added to the emulsion and the emulsion stirred to cross-link the albumin. The microspheres can then be isolated by centrifugation, the oil removed and the spheres washed, e.g. with petroleum ether followed by ethanol.  
25 Finally, the microspheres can be sieved and collected and dried by filtration.

Starch microspheres can be prepared by adding a warm aqueous starch solution, e.g. of potato starch, to a heated solution of polyethylene glycol

in water with stirring to form an emulsion. When the two-phase system has formed (with the starch solution as the inner phase) the mixture is then cooled to room temperature under continued stirring whereupon the inner phase is converted into gel particles. These particles are then filtered off  
5 at room temperature and slurried in a solvent such as ethanol, after which the particles are again filtered off and laid to dry in air.

The microspheres can be hardened by well known cross-linking procedures such as heat treatment or by using chemical cross-linking  
10 agents. Suitable agents include dialdehydes, including glyoxal, malondialdehyde, succinaldehyde, adipaldehyde, glutaraldehyde and phthalaldehyde, diketones such as butadione, epichlorohydrin, polyphosphate and borate. Dialdehydes are used to cross-link proteins such as albumin by interaction with amino groups, and diketones form  
15 schiff bases with amino groups. Epichlorohydrin activates compounds with nucleophiles such as amino or hydroxyl to an epoxide derivative.

Doses of the drug, e.g. THC, in the range 0.25 to 40 mg per day can be administered, a preferred range is 0.5 to 30 mg per day and a more  
20 preferred range 1 to 20 mg per day.

The present invention is now illustrated but not limited with reference to the following examples.

25 Example 1 An emulsion formulation of THC based on a vegetable oil

THC is dissolved in sesame oil to give a concentration of 35 mg/ml. Water containing the dispersed emulsifying agent Lipoid E80 at 1.5% w/v (i.e. 1.5 g of Lipoid E80 per 100mls of water) is used as the continuous

phase. The sesame oil-THC mixture is dispersed in the aqueous phase using a Silverson Mixer (Silverson Machine UN) in order to produce a course emulsion. The course emulsion is then passed through an APV. Lab 40 homogeniser to produce a fine emulsion of particles having an average size (i.e. diameter) of 250 nm as measured by Photon correlation spectroscopy. A small quantity, e.g. 1 % w/w on the total weight of the oil phase, of tocopherol can be added to the oil phase to provide a stabilizing function. The total oil content of the final emulsion is 20% w/v, i.e. the emulsion contains 20 g of oil per 100 mls thereof. The emulsion formulation of THC could be delivered to the nasal cavity using known nasal spray devices. The preferred volume for nasal administration is 150 µl (per nostril) containing a dose of about 1 mg of THC.

Example 2                      Castor oil emulsion formulation

The formulation is produced as described in Example 1 except the sesame oil phase is exchanged with castor oil. The particle size of the emulsion will be about 280 nm as measured by photon correlation spectroscopy.

Example 3                      Vitamin E emulsion formulation

The formulation is produced as described in Example 1 except the oil phase is exchanged with all-rac- $\alpha$ -tocopherol (no additional antioxidant is then required) and sodium deoxycholate co-emulsifier is added to the aqueous phase containing the Lipoid E80 at a concentration of 1 % w/v, i.e. 1 g of sodium deoxycholate per 100 mls of water.

Example 4                      Cyclodextrin/microsphere formulation

Hydroxypropyl cyclodextrin is dissolved in water to a concentration of 100 mg/ml. THC is added to provide a concentration in the cyclodextrin solution of 10 mg/ml. The product is freeze-dried to produce a fluffy white powder. The freeze dried powder is mixed with starch microspheres (obtained from Perstorp, Sweden). The weight ratio of freeze-dried THC/cyclodextrin product to microspheres can be varied but a weight ratio of 1:1 is preferred. In order to obtain a dose of 1 mg of THC, 10 mg of the freeze dried product is mixed with 10 mg of the starch microspheres. The powdered product can be delivered using an insufflator device.

Example 5                      Albumin microsphere formulation

THC is dissolved in ethanol to provide a concentration of 100 mg/ml. The ethanolic solution of THC is then mixed slowly with human serum albumin (B.P) containing about 20% w/v, i.e. 20 g of albumin per 100 ml, of total protein to give a concentration of THC of 10 mg/ml in the albumin solution. The solution is then spray dried using a LabPlant spray drier at standard operating conditions. The resultant albumin microspheres are collected. These have an average size (i.e. diameter) of about 30  $\mu\text{m}$  as measured using a Malvern Mastersizer apparatus. A dose of 20 mg of the powder could be administered nasally using an insufflator device familiar to the skilled artisan.

Example 6

200 mg of THC dissolved in 2 ml of ethanol was added to 6 ml of sesame oil. The oil/ethanol/THC solution was stirred in an open vessel for 2  
5 hours at 50-60°C to evaporate the majority of the ethanol. Into 20 ml of 0.9% sodium chloride solution was dispersed 360 mg of egg yolk phospholipid (Lipoid E80) by warming to 40-50°C. The oil was added to the phospholipid dispersion and the two phases coarsely emulsified using an IKA laboratory homogeniser at 20,000 rpm for 2 minutes. This  
10 emulsion was then transferred to an APV Rannie Mini-Lab valve homogeniser and passed through twice at 500 bar to produce a milky off-white product. The final product contained 6.7 mg/ml THC. A nasal administration of 150 µl of the emulsion would provide 1 mg of THC.

15 Example 7

1 g of cross-linked starch microspheres (Eldexomer™, Perstorp Pharma, Sweden) were weighed into a glass vial. 1 ml of 25 mg/ml THC in ethanol was added to the starch microspheres. The vial containing  
20 microspheres suspended in THC solution was transferred to a water bath at 70°C to evaporate the ethanol. After 3 hours, the majority of the ethanol had evaporated. The product was transferred from the vial into a small tray and dried in an oven at 60°C for 1 hour. The lightly aggregated microspheres were broken up using a spatula to form a free-  
25 flowing powder. 41 mg of powder contained a 1 mg dose of THC.



Example 8

1 g of human serum albumin (Sigma) was dissolved in 50 ml of water. 2 ml of 25 mg/ml THC in ethanol was added to the albumin solution to form  
5 a cloudy dispersion. The dispersion was processed using a LabPlant SD-05 spray drier (175°C inlet temperature, 0.1 mm nozzle diameter, airflow 20-22 'units', atomising pressure 1.8 bar, pump speed 10 ml/min). The result was 0.33 grams of powder (31 % yield) which had a particle size (determined using light microscopy) in the range 1-10 µm.

10

## Claims:

1. A composition for nasal delivery comprising a cannabinoid in a biphasic delivery system.
- 5 2. A composition according to Claim 1, wherein the biphasic delivery system is an oil-in-water emulsion.
3. A composition according to Claim 2, wherein the oil phase in the  
10 emulsion system is a vegetable oil.
4. A composition according to Claim 3, wherein the oil phase in the emulsion system is castor oil.
- 15 5. A composition according to Claim 2, wherein the oil phase in the emulsion system is tocopherol.
6. A composition according to any one of Claims 2 to 5, wherein the emulsifier is a phospholipid.
- 20 7. A composition according to any one of Claims 2 to 5, wherein the emulsifier is a block copolymer.
8. A composition according to Claim 1, wherein the biphasic delivery  
25 system comprises a solubilising agent for the cannabinoid.
9. A composition according to Claim 1, wherein the biphasic delivery system is a microsphere system comprising a material accommodating the

cannabinoid which is encapsulated by or dispersed on the surface of a microsphere carrier matrix.

10. A composition for nasal delivery comprising a cannabinoid in a  
5 microsphere delivery system.

11. A composition according to Claim 10, wherein the microspheres are made of albumin.

10 12. A composition according to Claim 11, wherein the selected albumin microspheres are produced by a process of spray drying.

13. A composition according to any one of Claims 1 to 12, wherein the cannabinoid is dronabinol.

15

14. A method for the treatment of pain, nausea or appetite loss which comprises administration of a composition according to any one of Claims 1 to 13 to a patient in need of such treatment.

20 15. The use of a cannabinoid in the manufacture of a composition according to any one of Claims 1 to 13 for treating a patient in need of a cannabinoid.

16. The use of a cannabinoid in the manufacture of a composition  
25 according to any one of Claims 1 to 13 for treating pain or nausea or to stimulate appetite.

17. The use of a composition according to any one of Claims 1 to 13 for the manufacture of a medicament for treating a patient in need of a cannabinoid.

5 18. The use of a composition according to any one of Claims 1 to 13 for the manufacture of a medicament for treating pain or nausea or to stimulate appetite.

19. The use of a cannabinoid in the manufacture of a composition  
10 according to any one of Claims 1 to 13 for nasal delivery.

20. The use of a composition according to any one of Claims 1 to 13 for the manufacture of a medicament for nasal delivery.

15

# INTERNATIONAL SEARCH REPORT

Internati	Application No
PCT/GB 98/03703	

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K31/35 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 82 03768 A (KENTUCKY RESEARCH FOUNDATION) 11 November 1982 cited in the application see claims see page 11, line 7 - line 15 ---	1-20
A	US 5 447 729 A (G.W.BELENDUIK ET AL.) 5 September 1995 see claims 1,4,16 see column 5, line 7 - line 8 see column 2, line 12 - line 13 ---	1-20
A	EP 0 266 443 A (A.W.JACOBS) 11 May 1988 see claims see column 1, line 13 - line 20 see column 2, line 45 - line 53 ---	1-20
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier document but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
 "&" document member of the same patent family

Date of the actual completion of the international search

8 June 1999

Date of mailing of the international search report

15/06/1999

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Scarponi, U

# INTERNATIONAL SEARCH REPORT

Internat I Application No

PCT/GB 98/03703

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 11668 A (YISSUM) 3 Apr11 1997 see claims 1,14-19 ---	1-20
A,P	WO 98 29096 A (INHALE THERAPEUTIC SYSTEMS) 9 July 1998 see claims 1,8,10,11,17 -----	1-20

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/03703

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 14  
is(are) directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/GB 98/03703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8203768 A	11-11-1982	US 4464378 A AU 8524782 A CA 1183778 A EP 0077393 A	07-08-1984 24-11-1982 12-03-1985 27-04-1983
US 5447729 A	05-09-1995	AU 695053 B AU 2276095 A CA 2187202 A EP 0754031 A JP 9511744 T WO 9527479 A	06-08-1998 30-10-1995 19-10-1995 22-01-1997 25-11-1997 19-10-1995
EP 266443 A	11-05-1988	DE 3688617 T JP 63130533 A US 4635651 A	18-11-1993 02-06-1988 13-01-1987
WO 9711668 A	03-04-1997	AU 6942096 A CA 2231764 A EP 0876143 A	17-04-1997 03-04-1997 11-11-1998
WO 9829096 A	09-07-1998	AU 5719798 A AU 5806898 A AU 5806998 A AU 6014098 A WO 9829140 A WO 9829141 A WO 9829098 A	31-07-1998 31-07-1998 31-07-1998 31-07-1998 09-07-1998 09-07-1998 09-07-1998